Showing results (231-240 of 247) with videos related to
Sort By:
Pageof 25
Clinical Pharmacology and Therapeutics|August 11, 2017
New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision MedicineM V Relling, R M Krauss, D M Roden, et al.Clinical Pharmacology and Therapeutics|December 27, 2012
The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metforminS L Stocker, K M Morrissey, S W Yee, et al.Clinical Pharmacology and Therapeutics|May 24, 2012
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathyR A Wilke, L B Ramsey, S G Johnson, et al.Clinical Pharmacology and Therapeutics|December 24, 2015
Physician response to implementation of genotype-tailored antiplatelet therapyJ F Peterson, J R Field, K M Unertl, et al.The Pharmacogenomics Journal|October 1, 2014
A polymorphism in HLA-G modifies statin benefit in asthmaD Naidoo, A C Wu, M H Brilliant, et al.Clinical Pharmacology and Therapeutics|June 29, 2012
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotypingJ S Schildcrout, J C Denny, E Bowton, et al.Clinical Pharmacology and Therapeutics|December 23, 2011
Predicting clopidogrel response using DNA samples linked to an electronic health recordJ T Delaney, A H Ramirez, E Bowton, et al.Clinical Pharmacology and Therapeutics|May 24, 2014
Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metforminS Goswami, S W Yee, S Stocker, et al.Clinical Pharmacology and Therapeutics|June 12, 2014
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 updateL B Ramsey, S G Johnson, K E Caudle, et al.Clinical Pharmacology and Therapeutics|October 8, 2013
Characterization of statin dose response in electronic medical recordsW-Q Wei, Q Feng, L Jiang, et al.Pageof 25